Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | NANP | Q8TBE9 | 3/20 | 0.39 |
| ▸ | NEU1 | Q99519 | 5/20 | 0.32 |
| ▸ | NEU3 | Q9UQ49 | 5/20 | 0.32 |
| ▸ | NEU2 | Q9Y3R4 | 5/20 | 0.32 |
| ▸ | NEU4 | Q8WWR8 | 5/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15471527 | 1.00 | L3MBTL1 (0.54) | L3MBTL1NANPNEU1NEU3NEU2 | |
| SCHEMBL12731860 | 1.00 | L3MBTL1 (0.54) | L3MBTL1NANPNEU1NEU3NEU2 | |
| SCHEMBL12302605 | 1.00 | L3MBTL1 (0.54) | L3MBTL1NANPNEU1NEU3NEU2 | |
| SCHEMBL16272856 | 1.00 | L3MBTL1 (0.54) | L3MBTL1NANPNEU1NEU3NEU2 | |
| SCHEMBL14648888 | 1.00 | L3MBTL1 (0.54) | L3MBTL1NANPNEU1NEU3NEU2 | |
| SCHEMBL10077901 | 0.90 | L3MBTL1 (0.43) | L3MBTL1NANP | |
| SCHEMBL8905452 | 0.88 | L3MBTL1 (0.55) | L3MBTL1NANPNEU1NEU3NEU2 | |
| SCHEMBL15143127 | 0.88 | L3MBTL1 (0.44) | L3MBTL1NANP | |
| SCHEMBL15806332 | 0.86 | L3MBTL1 (0.53) | L3MBTL1NANPNEU1NEU3NEU2 | |
| SCHEMBL17936315 | 0.86 | L3MBTL1 (0.53) | L3MBTL1NANPNEU1NEU3NEU2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170007712-A1 | GLYCOPEGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE METHODS | NOVO NORDISK A/S (DK) | 2017-01-12 | — | — | US | disclosed |
| US-20160200795-A1 | FACTOR VIII: REMODELING AND GLYCOCONJUGATION OF FACTOR VIII | NOVO NORDISK A/S (DK) | 2016-07-14 | — | — | US | disclosed |
| US-20160193353-A1 | FACTOR VIII: REMODELING AND GLYCOCONJUGATION OF FACTOR VIII | NOVO NORDISK A/S (DK) | 2016-07-07 | — | — | US | disclosed |
| US-9237764-B2 | Production of 6′-O-sialyllactose and intermediates | GLYCOM A/S (DK) | 2016-01-19 | — | — | US | disclosed |
| US-20150343080-A1 | GLYCOPEGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE METHODS | NOVO NORDISK AS (DK) | 2015-12-03 | — | — | US | disclosed |
| US-8853161-B2 | Glycopegylation methods and proteins/peptides produced by the methods | NOVO NORDISK A/S (DK) | 2014-10-07 | — | — | US | disclosed |
| US-20140294762-A1 | GLYCOPEGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE METHODS | NOVO NORDISK A/S (DK) | 2014-10-02 | — | — | US | disclosed |
| US-20140170728-A1 | Factor IX: Remodeling and Glycoconjugation of Factor IX | NOVO NORDISK A/S (DK) | 2014-06-19 | — | — | US | disclosed |
| US-20130035481-A1 | PRODUCTION OF 6'-O-SIALYLLACTOSE AND INTERMEDIATES | GLYCOM A/S (DK) | 2013-02-07 | — | — | US | disclosed |
| US-20120220517-A1 | Glycopegylation Methods and Proteins/Peptides Produced by the Methods | NOVO NORDISK A/S (DK) | 2012-08-30 | — | — | US | disclosed |
| US-20100015684-A1 | FACTOR VII: REMODELING AND GLYCOCONJUGATION OF FACTOR VII | NEOSE TECHNOLOGIES, INC. | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200795-A1 | FACTOR VIII: REMODELING AND GLYCOCONJUGATION OF FACTOR VIII | F13B, F8, F13A1 | L3MBTL1 3461/4885NANP 473/4885NEU1 217/4885 |
| US-20120220517-A1 | Glycopegylation Methods and Proteins/Peptides Produced by the Methods | PTMS, ANPEP, NGLY1 | L3MBTL1 1974/4885NANP 341/4885NEU1 88/4885 |
| US-20160193353-A1 | FACTOR VIII: REMODELING AND GLYCOCONJUGATION OF FACTOR VIII | F13B, F8, F13A1 | L3MBTL1 3461/4885NANP 473/4885NEU1 217/4885 |
| US-20100015684-A1 | FACTOR VII: REMODELING AND GLYCOCONJUGATION OF FACTOR VII | F13B, F7, HABP2 | L3MBTL1 2634/4885NANP 656/4885NEU1 187/4885 |
| US-20170007712-A1 | GLYCOPEGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE METHODS | PTMS, ANPEP, NGLY1 | L3MBTL1 1974/4885NANP 341/4885NEU1 88/4885 |
| US-20130035481-A1 | PRODUCTION OF 6'-O-SIALYLLACTOSE AND INTERMEDIATES | ST6GAL1, FUT6, FUT5 | L3MBTL1 4417/4885NANP 76/4885NEU1 14/4885 |
| US-20150343080-A1 | GLYCOPEGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE METHODS | PTMS, ANPEP, NGLY1 | L3MBTL1 1974/4885NANP 341/4885NEU1 88/4885 |
| US-20140294762-A1 | GLYCOPEGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE METHODS | PTMS, ANPEP, NGLY1 | L3MBTL1 1974/4885NANP 341/4885NEU1 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.